Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Raflesia Journal of Language and Health
Lesmana, Vienna Alodia
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Education Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
THE EXPRESSION OF HER-2 AND GALECTIN-3 IN COLORECTAL ADENOCARCINOMA AND THEIR RELATIONSHIP WITH CLINICOPATHOLOGICAL PARAMETERS Lesmana, Vienna Alodia
JURNAL KEDOKTERAN RAFLESIA Vol. 6 No. 2 (2020)
Publisher : UNIVERSITAS BENGKULU

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33369/juke.v6i2.13785

Abstract

Colorectal carcinoma (CRC) is the third most common cancer among worldwide. Data from WHO GLOBOCAN in 2018 show there were 1.8 million cases of CRC in the world, with mortality rates 861,000. Histopathology of tumor show 90% of CRC is adenocarcinoma and predominantly in men. Some proteins that are thought to play a role in tumor development are HER2 and Galectin-3. Correlation between expression of Human Epidermal Growth Factor Receptor 2 (HER2)  and Galectin-3 with clinicopathology aspect are expected to help determine treatment options. The aim of this study was to investigate the correlation between expression levels of HER-2 and Galectin-3 in vary clinicopathological aspect of colorectal adenocarcinoma. Cross sectional study was conducted in 40 samples of colorectal adenocarcinoma in dr. Kariadi Central General Hospital from 1st  January 2018 until 31st  December 2018. Samples were analyzed regarding the expression of HER2 and Galectin-3 by immunohistochemical staining of paraffin-embedded material. Coexpression of HER-2, Galectin-3 and the clinicopathological parameters (gender, age, location, depth of invasion, lymph nodes metastase, distant metastase and stage) were analyzed using Chi square test and Spearmans correlation test. Positive HER-2 expression was found on 5% of samples, while strong expresion of Galectin-3 was found on 12.5% of samples. There was no significant correlation between HER-2 and Galectin-3 expression and clinicopathology aspect.
Case Report: Primary Breast Diffuse Large B-Cell Lymphoma Lesmana, Vienna Alodia; Putra, Michael Setiawan; Wirastuti, Elia
Journal of Language and Health Vol 6 No 2 (2025): Journal of Language and Health
Publisher : CV. Global Health Science Group

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37287/jlh.v6i2.7154

Abstract

Background: Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare entity, accounting for less than 0.5% of all primary breast malignancies and less than 1% of all non-Hodgkin lymphomas. It is often challenging to diagnosed due to its clinical and histopathological resemblance to invasive breast carcinoma. Objective: To report the diagnostic journey and histopathological characteristics of a rare case of primary breast DLBCL and to highlight the importance of immunohistochemical examination in establishing an accurate diagnosis. Methods: This case report documents a 47-year-old female patient presenting with a right breast mass. The diagnosis was established through histopathological examination using Hematoxylin and Eosin (H&E) staining and immunohistochemical analysis. Results: Initial histopathology suggested the possibility of medullary-pattern invasive breast carcinoma with a differential diagnosis of large-cell lymphoma. Immunohistochemical analysis revealed diffuse positive expression of CD20, negative expression of CK5/6 and CD3, and a Ki67 proliferation index exceeding 30%. These findings confirmed the diagnosis of primary breast DLBCL. Conclusion: Primary breast DLBCL is a rare malignancy that should be considered as a differential diagnosis for high-grade breast tumors. Histopathological and immunohistochemical examinations play a crucial role in ensuring an accurate diagnosis. The primary treatment approach involves systemic chemotherapy with or without radiotherapy, while radical mastectomy is not recommended as it may worsen the patient's prognosis. Keywords: Primary breast lymphoma; Diffuse large B-cell lymphoma; Breast tumor; Histopathology; Immunohistochemistry; Case report.
Co-Authors Putra, Michael Setiawan Wirastuti, Elia